New ways to administer daratumumab and isatuximab get positive recommendations from EMAAccess10 April 2026
Join our webinar “The generics market in Europe and implications for cancer treatment and care”Access, MPE5 March 2026
US Food and Drug Administration (FDA) issues draft guidance on minimal residual diseaseAccess28 January 2026
Watch our webinar “How are costs and medicine effectiveness part of decision-making in medicine access?”Access, Videos15 October 2025
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, Myeloma27 June 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
